The results of the well-conducted trial by Saad et al. (1) have prompted many to consider routine use of zoledronic acid to reduce the incidence of skeletal-related events in minimally symptomatic or asymptomatic men with hormone-refractory prostate cancer. This is a somewhat troublesome proposition, because all men in this situation are not at risk of a skeletal-related event.
In the placebo arm of the trial (1), the rate of skeletal-related events was 44.2%, and thus more than half the men participating in the trial never experienced a skeletal-related event. Higher rates of fatigue, anemia, myalgia, fever, lower limb edema, dizziness, and weight loss were reported by men who received zoledronic acid than by men who received placebo. Thus, there is a good rationale for avoiding this treatment in men at little risk for a skeletal-related event.
Uni-and multivariable analyses of baseline patient characteristics and treatment received are usually included in reports of large, randomized trials. Typically these analyses identify independent predictors of the primary outcome and adjust the treatment effect for chance imbalances in these predictors, increasing the precision of the treatment effect (2) . Compared with men who received placebo, men who received zoledronic acid at 4 mg had fewer prior skeletal-related events (30.8% versus 37.5%) and had longer median survival (546 days versus 464 days), suggesting subtle differences between these groups at baseline that may have influenced the observed rates of skeletal-related events (3, 4) . Even small differences in important predictors can have a major impact if the variable is important enough (2) . Little is known about predictors of skeletalrelated events in men with hormonerefractory prostate cancer, but clearly such information could help clinicians identify those patients at highest risk for a skeletal-related event and those most likely to benefit from zoledronic acid therapy (5) . We request that the authors provide these data to help clinicians determine the most logical use of this drug for their patients.
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. However, we believe that the evidence supports the routine use of zoledronic acid in these patients. After 24 months of follow-up, 49% of patients in the placebo arm had experienced at least one SRE (2), suggesting that patients with bone metastases from advanced prostate cancer are at substantial risk of skeletal complications. In fact, the risk is similar to that observed in patients with stage III multiple myeloma (51% incidence at 21 months) (3), for which intravenous bisphosphonate therapy has been the standard of care for years. Moreover, the mean annual incidence of SREs among prostate cancer patients in the placebo arm is approximately 1.5 events per year (2), indicating that patients often have multiple events each year. Because these patients have a median survival of 12-53 months from the time of diagnosis of bone metastases (4), the likelihood that any given patient will experience a skeletal complication is high. More important, skeletal complications are associated with decreased quality of life (5) and survival (6) . Therefore, we believe there is sound clinical rationale for proactive treatment with zoledronic acid in patients with bone metastases from advanced prostate cancer and that the potential benefits outweigh the risks associated with bisphosphonate therapy. Adverse events associated with zoledronic acid were primarily mild-to-moderate flulike symptoms and would not be expected to affect quality of life to the same extent as skeletal complications.
Drs. Winquist and Berry also point out subtle differences in the treatment groups, such as differences in the percentage of patients with an SRE before study entry, and suggest that these differences may have influenced the outcome of the trial. Exploratory analyses have shown that this imbalance, which was not statistically significant, did not affect the outcome of the trial. Before study entry, 30.8% of patients in the 4 mg of zoledronic acid group and 37.5% in the placebo group had experienced an SRE. After adjusting for prior SRE, compared with patients in the placebo group, the percentage of patients with an SRE was lower for patients in the zoledronic acid group (P ϭ .037, logistic regression analysis), and the time to first SRE was longer for patients in the zoledronic acid group (adjusted hazard ratio ϭ 0.684, 95% confidence interval ϭ 0.510 to 0.918; P ϭ .011). A stratified analysis showed that zoledronic acid was associated with an absolute 10% reduction in the percentage of patients with at least one SRE, regardless of whether patients did or did not have an SRE before study entry (2) .
Finally, Drs. Winquist and Berry ask if there are any data on prognostic factors that might predict the risk of SREs and that could be used to guide treatment decisions. Although there are data to suggest that some patients are at higher risk of SREs than others, to date, there is no way to predict with any degree of certainty who will experience skeletal complications. Two factors that appear to predict a higher risk for skeletal complications include previous SRE and high levels of the bone resorption marker N-telopeptide (NTX). Patients who experienced an SRE before study entry were slightly more likely to experience a subsequent SRE (2); however, the urinary NTX/creatinine ratio may be the strongest predictor of the risk of SREs. A detailed retrospective analysis of prostate cancer patients' most recent NTX levels before an SRE indicated that patients with the highest levels of NTX excretion (Ն100 nmol/mmol of creatinine) had a fivefold increased risk of SREs (7) . Moreover, high NTX excretion was associated with disease progression in bone and was indicative of immediate risk of an event. Although bone resorption markers may be useful for monitoring disease progression and response to bisphosphonate therapy, they should not be used to determine when to initiate treatment with bisphosphonates. The use of biochemical markers of bone resorption for making treatment decisions is not supported by American Society of Clinical Oncology guidelines for the treatment of bone metastases from breast cancer. This would require prospective clinical trials.
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